2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 506

The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis
Abstract Number: 1712

The Relationship Between Physical Functioning and Work for People with Psoriatic Arthritis: Results from a Large Real-World Study in 16 Countries
Abstract Number: 529

The Relationship Between Promis and CDAI Scores, Disease Duration, Age and Gender in Patients with Rheumatoid Arthritis
Abstract Number: 240

The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease
Abstract Number: 117

The Relationship Between Socioeconomic Factors and Dmards Use in Rheumatoid Arthritis
Abstract Number: 855

The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome
Abstract Number: 495

The Relative Performance of 28-Joint Disease Activity Score Based on C-Reactive Protein with Three Versus Four Components in Patients with Rheumatoid Arthritis
Abstract Number: 1274

The Reproducibility of a Semi-Automatic Algorithm in the Detection of Cortical Breaks and Adjacent Trabecular Bone Loss in Scan-Rescan Data from Patients with Early Arthritis
Abstract Number: 1324

The Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Abstract Number: 1013

The Risk of Colchicine Associated Myopathy in Gout: Influence of Concomitant Use of Statin
Abstract Number: 1705

The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Number: 402

The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Abstract Number: 1074

The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies
Abstract Number: 1784

The Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 1993

The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].